CancerDECIDES B+NCT06191679
Decision Aid for Education and Support About Cancer Treatment
A study testing Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention) in people with Cancer and Childhood Cancer, run by Children's Hospital of Philadelphia at 1 site in United States.
Trial summary
The goals of this clinical trial are to evaluate DECIDES, a web-based decision support application that provides education about cancer and cancer treatment and provides support to encourage adolescent and young adult (AYA) patients, their caregivers, and oncology health care providers to make informed decisions about… Read more about this study
- Who is it for?
- Ages 15 to 24 yearsHealthy volunteers can take part
- Conditions the study is for
- Cancer, Childhood Cancer
- What is being tested?
- Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 117 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Jul 2020to 13 Apr 2023
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 24 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Adolescent and Young Adults (AYA)
- INCLUSION CRITERIA:
- Ages 15-24 years old
- Newly diagnosed or relapsed with leukemia/lymphoma, solid tumor, or brain tumor within 6 weeks of enrollment
- Ability to read and speak English
- If <18 Years Old: Parental/guardian permission to participate (informed consent)
- EXCLUSION CRITERIA:
- Inability to read or speak English
- Pre-existing cognitive deficits (based on provider assessment) that result in impaired reading or decision-making capacity
- AYA is a ward of the state or any other agency, institution, or entity
- If <18 Years Old: No Parental/Guardian permission to participate (informed consent)
Caregivers
- INCLUSION CRITERIA:
- Parent or Legal Guardian of a participating AYA
- Ability to read and speak English
- EXCLUSION CRITERIA:
- Foster parent or child advocate (i.e., caregiver is not biological parent or legal guardian)
- Inability to read or speak English
Oncology Clinicians
- INCLUSION CRITERIA:
- Oncology clinician involved in decision-making about cancer treatment with enrolled AYA patients and caregiver(s)
- Ability to read and speak English
- EXCLUSION CRITERIA:
- Oncology clinician that is not involved in decision-making about cancer treatment with enrolled AYA patients and caregiver(s)
- Inability to read or speak English
Trial locations and contacts
1 site in 1 country.
United States1 site
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
About this study
The goals of this clinical trial are to evaluate DECIDES, a web-based decision support application that provides education about cancer and cancer treatment and provides support to encourage adolescent and young adult (AYA) patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
The main questions this study aims to answer are:
Read more
- Is DECIDES acceptable, usable, and feasible for AYA, caregivers, and oncology health care providers?
- Is DECIDES helpful for AYA, caregivers, and oncology health care providers that are making cancer treatment decisions together?
AYA and caregiver participants will complete a questionnaire and be randomly assigned to participate in one of three groups: (1) Usual Care, (2) DECIDES, or (3) DECIDES+. Participants in 'Usual Care' will continue to have access to their oncology health care team for questions related to cancer and cancer treatment, as per usual standard of care. Participants in both 'DECIDES' and 'DECIDES+' groups will receive access to DECIDES, and those in 'DECIDES+' will receive additional live, coach-assisted support. After 8 weeks, AYA and caregivers will complete a follow-up questionnaire and those in the 'DECIDES' and 'DECIDES+' groups will complete a semi-structured qualitative interview. Oncology clinicians of participating AYA will be invited to participate in a semi-structured qualitative interview. Researchers will compare groups to see if AYA and caregivers that receive access to DECIDES (with an informational handout vs. coach-assisted support) report more positive decision-making processes compared to those that receive standard of care.
Read the detailed description
DECIDES is a developmentally appropriate, engaging, and interactive web-based decision support application that has been designed to address health literacy and includes:
- Education on cancer and cancer treatments, including clinical trials
- An exercise to identify perceived barriers and benefits to treatment options
- An exercise to clarify personal goals for treatment that align with life goals
- Resources to support communication with the oncology health care team
- Conditions
- Cancer, Childhood Cancer
- Being tested
- Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)
- Keywords
- AYA
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)Behavioural
DECIDES is a developmentally appropriate, engaging, and interactive web-based decision support intervention for AYA diagnosed with cancer (and their caregivers) that includes components written for low health literacy. Components include:
- Education on cancer and cancer treatments, including clinical trials
- An exercise to identify perceived barriers and benefits to treatment options
- An exercise to clarify personal goals for treatment that align with life goals
- Resources to support communication with the oncology health care team
| Study group | Role | What they receive |
|---|---|---|
| Usual Care | No intervention | Subjects will not receive the intervention and will only receive standard of care (i.e., subjects will access their health care team for decision support, per usual). |
| DECIDES with Informational Handout (DECIDES) | Experimental | Subjects will receive access to the decision support intervention (DECIDES) along with an informational handout that includes goals of the decision support intervention and instructions for accessing the web-based application independently. Receives: Behavioral: Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention) |
| DECIDES with Coach-Assisted Support (DECIDES+) | Experimental | Subjects will receive access to the decision support intervention (DECIDES) along with live coach-assisted support for accessing and navigating the web-based application. Receives: Behavioral: Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptability of Decision Aid
This is a 12-item study-team developed measure used to obtain acceptability ratings from AYA and caregivers (that completed participation in DECIDES or DECIDES+). This measure is based on The Ottawa Hospital's measure of acceptability regarding comprehension of components of a decision aid, its length, pace, amount of information, balance in presentation of information about options, and overall suitability for decision-making. Items are rated on a 5-point Likert scale (1=strongly disagree to 5=strongly agree). The average across 12 items is calculated to produce a total score that ranges from 1-5. Higher scores reflect greater acceptability. Two items related to the DECIDES Coach are not answered by participants in DECIDES who did not have access to a coach.
Measured: 8 weeks post-randomization
Usability of Decision Aid
This is a 10-item scale collected from AYA and caregivers (that completed participation in DECIDES or DECIDES + coach) and oncology health care providers to measure perceptions of DECIDES usability. Items are rated on a 5-point Likert scale (1=strongly disagree to 5=strongly agree) and summed to produce a total score that ranges from 0 to 100. Scores are normalized to produce a percentile ranking. A score >80.3 reflects letter grade "A" (adjective rating "excellent"); 68-80.3 reflects letter grade "B" (adjective rating "good"), 68 reflects letter grade "C" (adjective rating "OK"); 51-67 reflects letter grade "D" (adjective rating "poor"); and <51 reflects letter grade "F" (adjective rating "awful").
Measured: 8 weeks post-randomization
Secondary outcomes (8)
Perceived Involvement in Shared Treatment Decision-Making Process
The SDM-Q-9 is a valid and reliable 9-item patient-reported questionnaire collected from AYA to measure their perceived involvement in the process of shared treatment decision-making with their oncology clinician. The physician version of the SDM-Q-9 (SDM-Q-Doc) was adapted for use with caregivers in this study to measure AYA involvement in shared decision-making with their oncology clinician, from the caregiver's perspective. Total scores range from 0 to 100. Higher scores reflect greater degree to which AYA were involved in a shared treatment decision-making process.
Measured: 8 weeks post-randomization
Perceptions of Physician Engagement in Decision-Making Process
This is a 5-item scale that measures AYA and caregiver perceptions of the extent to which clinicians engaged in five key elements of the decision-making process (e.g., discuss the available options with you in a way you could understand?, encourage you to ask questions or express any concerns you had about the available options?, involve you as much as you wanted in the decision making process?). The overall physician style score ranges from 0-100. Higher scores reflect more optimal communication with physician.
Measured: 8 weeks post-randomization
Knowledge of Cancer Clinical Trials
This is a 25-item true/false questionnaire used to assess participant understanding of clinical trials and informed consent processes. Items are scored based on % correct, with higher scores reflecting more knowledge.
Measured: 8-weeks post randomization
Attitudes Toward Cancer Clinical Trials
This is a 35-item measure of AYA and caregiver attitudes toward clinical trials. Continuous scores were calculated from PRPQ items reflecting 'Perceived Benefits' (with a higher score suggesting positive attitudes) and from PRPQ items reflecting 'Perceived Barriers' (with a higher score suggesting negative attitudes). A 'Decision Balance' score was computed by converting the 'Perceived Benefits' and 'Perceived Barriers' scores to Z-scores, and then subtracting the 'Perceived Barriers Z-scores' from the 'Perceived Benefits Z-scores'. A 'Decision Balance' Z-score of 0 represents the population mean; a positive valence (3) reflects more positive attitudes to clinical trials and negative valence (-3) reflects more negative attitudes.
Measured: 8 weeks post-randomization
Uncertainty in Cancer Treatment Decision-Making Process
This is a valid and reliable 16-item scale collected from AYA and caregivers to measure uncertainty in making cancer treatment decisions, including factors that contribute to uncertainty about cancer treatment options and perceptions of effective decision-making. Total scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict).
Measured: 8 weeks post-randomization
Regret About Cancer Treatment Decision-Making Process
This is a valid and reliable 5-item scale collected from AYA and caregivers to measure distress or remorse about a cancer treatment decision. Total scores range from 0 (no regret) to 100 (high regret).
Measured: 8 weeks post-randomization
Satisfaction With Cancer Treatment Decision-Making Process
This is a valid and reliable 6-item scale collected from AYA and caregivers to measure satisfaction with the cancer treatment decision that was made. Total scores range from 6 to 30, with higher scores reflecting higher satisfaction.
Measured: 8 weeks post-randomization
Self-confidence in Cancer Treatment Decision-Making Abilities
This is a valid and reliable 11-item scale collected from AYA and caregivers to measure self-confidence in decision-making abilities. Total scores range from 0 (not confident) to 100 (extremely confident).
Measured: 8 weeks post-randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2024
- Study start8 Jul 2020
- Primary completion13 Apr 2023
- Study completion13 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Children's Hospital of PhiladelphiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Family Units (AYA and caregiver participants) are randomized to one of three arms: 1. No intervention (referred to as "Usual Care") 2. DECIDES with an informational handout (referred to as "DECIDES") 3. DECIDES with coach-assisted support (referred to as "DECIDES+") Oncology Clinicians of participating AYA are not randomized to an intervention arm; they are enrolled to complete a singular Qualitative Interview to provide feedback for future implementation.
- Masking
- None (open label)
- Enrolment
- 117 participants (actual)
Sponsor and investigators
- Lead sponsor
- Children's Hospital of Philadelphia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lamia Barakat, PhD, Principal investigator, Children's Hospital of Philadelphia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06191679
- Sponsor's protocol ID
- 20-017521
- Acronym
- DECIDES B+
- Status last verified
- Nov 2024
- First submitted
- 20 Dec 2023
- Last updated
- 6 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Barakat LP, Hammer SN, Wen Y, Anil A, Schwartz LA, Reilly A, Bagatell R, Schapira MM, Li Y, Deatrick JA. Evaluation of a Decision Support Intervention for Adolescents and Young Adults Newly Diagnosed with Cancer: A Pilot Randomized Trial. MDM Policy Pract. 2025 Jun 26;10(1):23814683251344624. doi: 10.1177/23814683251344624. eCollection 2025 Jan-Jun.
PubMed 40584145
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Decision Aid for Education and Support About Cancer Treatment
- ClinicalTrials.gov ID
- NCT06191679
- Acronym / sponsor ID
- DECIDES B+ / 20-017521
- Conditions
- Cancer, Childhood Cancer
- Keywords
- AYA
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 117 participants (actual)
- Lead sponsor
- Children's Hospital of PhiladelphiaUniversity, hospital or other
- Study start
- 8 Jul 2020 (actual)
- Primary completion
- 13 Apr 2023 (actual)
- Study completion
- 13 Apr 2023 (actual)
- First posted
- 5 Jan 2024 (actual)
- Results
- Posted 6 Jan 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goals of this clinical trial are to evaluate DECIDES, a web-based decision support application that provides education about cancer and cancer treatment and provides support to encourage adolescent and young adult (AYA) patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
The main questions this study aims to answer are:
- Is DECIDES acceptable, usable, and feasible for AYA, caregivers, and oncology health care providers?
- Is DECIDES helpful for AYA, caregivers, and oncology health care providers that are making cancer treatment decisions together?
AYA and caregiver participants will complete a questionnaire and be randomly assigned to participate in one of three groups: (1) Usual Care, (2) DECIDES, or (3) DECIDES+. Participants in 'Usual Care' will continue to have access to their oncology health care team for questions related to cancer and cancer treatment, as per usual standard of care. Participants in both 'DECIDES' and 'DECIDES+' groups will receive access to DECIDES, and those in 'DECIDES+' will receive additional live, coach-assisted support. After 8 weeks, AYA and caregivers will complete a follow-up questionnaire and those in the 'DECIDES' and 'DECIDES+' groups will complete a semi-structured qualitative interview. Oncology clinicians of participating AYA will be invited to participate in a semi-structured qualitative interview. Researchers will compare groups to see if AYA and caregivers that receive access to DECIDES (with an informational handout vs. coach-assisted support) report more positive decision-making processes compared to those that receive standard of care.
Detailed description
DECIDES is a developmentally appropriate, engaging, and interactive web-based decision support application that has been designed to address health literacy and includes:
- Education on cancer and cancer treatments, including clinical trials
- An exercise to identify perceived barriers and benefits to treatment options
- An exercise to clarify personal goals for treatment that align with life goals
- Resources to support communication with the oncology health care team
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Family Units (AYA and caregiver participants) are randomized to one of three arms: 1. No intervention (referred to as "Usual Care") 2. DECIDES with an informational handout (referred to as "DECIDES") 3. DECIDES with coach-assisted support (referred to as "DECIDES+") Oncology Clinicians of participating AYA are not randomized to an intervention arm; they are enrolled to complete a singular Qualitative Interview to provide feedback for future implementation.
| Arm | Type | Receives |
|---|---|---|
| Usual Care | No intervention | –Subjects will not receive the intervention and will only receive standard of care (i.e., subjects will access their health care team for decision support, per usual). |
| DECIDES with Informational Handout (DECIDES) | Experimental | Behavioral: Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)Subjects will receive access to the decision support intervention (DECIDES) along with an informational handout that includes goals of the decision support intervention and instructions for accessing the web-based application independently. |
| DECIDES with Coach-Assisted Support (DECIDES+) | Experimental | Behavioral: Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)Subjects will receive access to the decision support intervention (DECIDES) along with live coach-assisted support for accessing and navigating the web-based application. |
Who may qualify
- Ages
- 15 to 24 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)DECIDES is a developmentally appropriate, engaging, and interactive web-based decision support intervention for AYA diagnosed with cancer (and their caregivers) that includes components written for low health literacy. Components include: * Education on cancer and cancer treatments, including clinical trials * An exercise to identify perceived barriers and benefits to treatment options * An exercise to clarify personal goals for treatment that align with life goals * Resources to support communication with the oncology health care team | Behavioural | DECIDES with Coach-Assisted Support (DECIDES+), DECIDES with Informational Handout (DECIDES) |
Primary outcome
Acceptability of Decision Aid
Time frame: 8 weeks post-randomization
This is a 12-item study-team developed measure used to obtain acceptability ratings from AYA and caregivers (that completed participation in DECIDES or DECIDES+). This measure is based on The Ottawa Hospital's measure of acceptability regarding comprehension of components of a decision aid, its length, pace, amount of information, balance in presentation of information about options, and overall suitability for decision-making. Items are rated on a 5-point Likert scale (1=strongly disagree to 5=strongly agree). The average across 12 items is calculated to produce a total score that ranges from 1-5. Higher scores reflect greater acceptability. Two items related to the DECIDES Coach are not answered by participants in DECIDES who did not have access to a coach.
Usability of Decision Aid
Time frame: 8 weeks post-randomization
This is a 10-item scale collected from AYA and caregivers (that completed participation in DECIDES or DECIDES + coach) and oncology health care providers to measure perceptions of DECIDES usability. Items are rated on a 5-point Likert scale (1=strongly disagree to 5=strongly agree) and summed to produce a total score that ranges from 0 to 100. Scores are normalized to produce a percentile ranking. A score >80.3 reflects letter grade "A" (adjective rating "excellent"); 68-80.3 reflects letter grade "B" (adjective rating "good"), 68 reflects letter grade "C" (adjective rating "OK"); 51-67 reflects letter grade "D" (adjective rating "poor"); and <51 reflects letter grade "F" (adjective rating "awful").
8 secondary outcomes
Perceived Involvement in Shared Treatment Decision-Making Process
Time frame: 8 weeks post-randomization
Perceptions of Physician Engagement in Decision-Making Process
Time frame: 8 weeks post-randomization
Knowledge of Cancer Clinical Trials
Time frame: 8-weeks post randomization
Attitudes Toward Cancer Clinical Trials
Time frame: 8 weeks post-randomization
Uncertainty in Cancer Treatment Decision-Making Process
Time frame: 8 weeks post-randomization
Regret About Cancer Treatment Decision-Making Process
Time frame: 8 weeks post-randomization
Satisfaction With Cancer Treatment Decision-Making Process
Time frame: 8 weeks post-randomization
Self-confidence in Cancer Treatment Decision-Making Abilities
Time frame: 8 weeks post-randomization
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40584145Barakat LP, Hammer SN, Wen Y, Anil A, Schwartz LA, Reilly A, Bagatell R, Schapira MM, Li Y, Deatrick JA. Evaluation of a Decision Support Intervention for Adolescents and Young Adults Newly Diagnosed with Cancer: A Pilot Randomized Trial. MDM Policy Pract. 2025 Jun 26;10(1):23814683251344624. doi: 10.1177/23814683251344624. eCollection 2025 Jan-Jun.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lamia Barakat, PhD principal investigator
Children's Hospital of Philadelphia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention) in people with Cancer and Childhood Cancer, run by Children's Hospital of Philadelphia at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acceptability of Decision Aid (time frame: 8 weeks post-randomization). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06191679, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2025.